CURRICULUM VITAE SAMPLE

Date of Revision: 08/01/2017

Name: Jialing Zhang, M.D., Ph.D.

Department & Organization: Department of Pathology, Yale School of Medicine, Yale University

Current Position: Postdoctoral Associate

Mentor: Dr. Samuel G. Katz MD,PhD

Education:

M.D. Inner Mongolia Medical School, Hohhot, People's Republic of China, 06/2002

M.Sc. Inner Mongolia Medical School, Hohhot, People's Republic China, 12/2008

Ph.D. Wuhan University, Wuhan, Hubei Province, People's Republic of China, 12/2015

Career/Academic Appointments:

2001-02 Intern, Department of Pediatrics, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, People's Republic of China

2002-05 Product Consultant, Jinchen Hai Si Phamaceutical Co., Ltd. Institute of Epidemiology and Microbiology, Chinese Academy of Preventive Medicine, Taiyuan, People's Republic of China

2006-08 Visiting Research Fellow, Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan

2009-11 Associate Research Scientist and Lecturer, Clinical Research Center of Affiliated Hospital, Inner Mongolia Medical School, Hohhot, People's Republic of China

2012-15 Graduate Student and Visiting Fellow, The Tumor Biology Section, Head and Neck Surgery, Branch of the NIDCD/NIH, USA

2015-15 Postgraduate student, Department of Genetics, Yale School of Medicine, Yale University, USA

2016-07.31.2017 Postdoctoral Associate, Department of Genetics, Yale School of Medicine, Yale University, USA

08.01.2017-Present: Postdoctoral Associate, Department of Pathology, Yale School of Medicine, Yale University, USA

Professional Honors & Recognition:

2014	First Prize for young medical research fellowship, Inner Mongolia Medical Association
2010	Inner Mongolia Young Scholarship Award for excellent thesis, Inner Mongolia Government
2009	Inner Mongolia Scientific & Technological advance award, Inner Mongolia Government

Training Courses and Workshops:

2013-14	"Principles of Clinical Pharmacology", NIH, Bethesda, USA
2014	"Translational Research in Clinical Oncology", NCI, NIH, Bethesda, USA
2014-15	"Molecular and cellular mechanisms of immunity", FAES, Bethesda, USA
2015	Workshop in "Grant application-writing", NIH, Bethesda, USA
2015	Workshop in "CAREERS IN CLINICAL TRIALS MANAGEMENT", NIH, Bethesda, USA
2015	IPA Analysis and metacore analysis, NIH, Bethesda, USA
2017	iPSC culture training, Stem Cell Center at Yale School of Medicine, New Haven, USA

Grant/Clinical Trials History:

Past Grants:

Agency: National Natural Science Foundation of China

I.D.# 81160253

Title: "The role of EZH2 in Non-small Cell Lung Cancer"

P.I.: Huqun Collaborator: Jialing Zhang, M.D.

Percent effort: 15%

Total costs for project period: RMB 560,000

Project period: 01/01/2012 - 12/31/2016

Agency: National Natural Science Foundation of Inner Mongolia

I.D.# 2011MS1158

Title: "The role of SEMA3B in Non-small Cell Lung Carcinoma"

P.I.: Jialing Zhang, M.D.

Percent effort: 80%

Total costs for project period: RMB 30,000

Project period: 6/1/2011 - 5/30/2013

Agency: Young Scholarship of Inner Mongolia Medical University

I.D.# 2010QN098

Title: "The role of SEMA3B in Non-small Cell Lung Carcinoma"

P.I.: Jialing Zhang, M.D.

Percent effort: 90%

Total costs for project period: RMB 10,000

Project period: 09/01/2010 -8/30/2012

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:
None

International/National:

2015.12.18 Biomarker Screening in Colorectal Cancer. Affiliated Hospital, Inner Mongolia Medical School, Hohhot, People's Republic of China

Regional:

None

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:

2015: IMMUNOLOGY Meeting, New Orleans, USA（Poster presentation): "Defective TRAF3 modulates alternative NF-kB signaling and cytokine expression to promote cancer cell survival in HPV positive head and neck cancer".

2014: AACR Annual Meeting, San Diego, USA（Poster presentation): "Alternative NF-κB pathway activation enhanced by deficient TRAF3 in human papillomavirus (HPV)-associated head and neck cancer."

2014: The NF-kappaB System in Health and Disease, Keystone Meeting, Colorado, USA (Poster presentation): "Defective TRAF3 promotes NF-κB signaling,cell survival, migration, and cytokine expression in HPV+ head and neck cancer".

Professional Service:
None

Peer Review Groups/Grant Study Sections:
None

Professional Societies:

2015 – Present	The American Association of Immunologists, Member
2014 – Present	Inner Mongolia Biochemistry and Molecular Biology Association, Board member
2014 – Present	Inner Mongolia Cell Biology Association, Board member
2012 – Present	American Association for Cancer Research, Member
2006 – Present	Japanese Cancer Association

Advisory Boards
None

Journal Service:
None

Professional Service for Professional Organizations:

Program Committee member of International Conference on Bioinformatics and Biomedicine in 2017

Yale University Service:

None

Public Service:

Supervision and Teaching Experience:

2013-14	Practical supervisor of special volunteer and summer student Stephan Schlitz, NIDCD/NIH, USA
2011-12	Practical supervisor of master degree student Jingjing Fan in Inner Mongolia, China
2009-11	Practical supervisor of master degree student XiaoYan Ren, in Inner Mongolia, China
2011-11	Protein purification
2010-10	RNA extraction
2010-10	DNA isolation
2009-11	Teaching of laboratory techniques (15 lectures on laboratory techniques for B.Sc and M.Sc in Inner Mongolian Medical University, China)
2009-09	Cell culture and transfection

Bibliography:

1. M. Hua, **Zhang**, J., J. Nan, and S. Bao. Clinical evaluation of neonatal intracranial hemorrhage with respiratory symptoms in 34 cases. *Inner Mongolia Medical Journal* 2004, 12:48-49.

2. J. Ma, W. Liang, R. Bu, and **Zhang, J.**, The application of fibrin glue in surgical treatment of human breast cancer. *Chinese Journal of Misdiagnostics* 2004,11:58-59.

3. M. Hua, L. Fu, J. MA, and **Zhang, J.**, The relationship between myocardial enzyme and apoptosis in peripheral blood lymphocytes in children with acute virus myocarditis. *Chinese Pediatric Emergency Medicine* 2006, 13:239-241.

4. **Zhang**, J., and X. Su. Effects of de-methylation in cancer treatment. *Chinese Journal of Misdiagnostics* 2006, 6:4531-4533.

5. **Zhang**, J., Hu,Q, L. Bi, and X. Su. The role of semaphorin3B in carcinogenesis. *Journal of Modern Oncology* 2008, 02:312-314.

6. H. Miyazawa, T. Tanaka, Y. Nagai, M. Matsuoka, Hu,Q, A. Sutani, K. Udagawa, **Zhang**, J., T. Hirama, Y. Murayama, N. Koyama, K. Ikebuchi, M. Nagata, M. Kanazawa, T. Nukiwa, S. Takenoshita, K. Kobayashi, and K. Hagiwara. Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. *Cancer Science* 2008, 99:595-600.

7. N. Koyama, **Zhang**, J., Hu. Q, H. Miyazawa, T. Tanaka, X. Su, and K. Hagiwara. Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B. *Oncogene* 2008, 27:6581-9.

8. Ren.X, Yan.Z, Hu.K, Su.X, Li.C, **Zhang,J**. Expression of phosphoinositide-3-kinase, protein kinase B and glucose transporter 4 is involved in insulin signaling conduction pathway in L6 rat skeletal myoblasts. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2011, 15:313-316.

9. J. Ma, **Zhang**, J., and Ming Liu. Expression of BRCA1 and p53 in sporadic breast cancer patients. *Journal of Practical Oncology* 2011, 26: 233-236.

15. **Zhang**, J., X. Su, M. Yan, *et al.,* Short hairpin RNA knockdown of EZH2 inhibits cell proliferation and migration in Human lung cancer cell line. *Chinese Journal of Clinicians* 2011, 5:5871-5874.

16. X. Wang, F. Zhang, L. Yang, Y. Mei, H. Long, X. Zhang, **Zhang, J.**, Qimuge.S, and X. Su. Ursolic acid inhibits proliferation and induces apoptosis of cancer cells *in vitro* and *in vivo*. *J Biomed Biotechnol* 2011, May, 419343.

17. H. Qun, **Zhang**, J., S. Muge, *et al*., The clinical therapeutic effect of mannatide and opioid combination on cancer pain. *Inner Mongolia Med Jounal,*2011, 43:143-145.

18. Hu. Q, **Zhang**, J., W. Su, *et al*., Comparative analysis of pathological characteristics between young-, middle-aged or elder patents with breast cancer. *Inner Mongolia Med Jounal,*2011, 43:294-297.

19. H. Qun, R. Ishikawa, **Zhang**, J., H. Miyazawa, Y. Goto, Y. Shimizu, M. Kanazawa, K. Kobayashi, K. Hagiwara, and N. Koyama. Enhancer of Zeste Homolog 2 Is a Novel Prognostic Marker in Non-small Cell Lung Cancer. *Cancer* 2012, 118:1599-606.

20. **Zhang**, J., X. Su, Y. Bi, *et al*., SEMA3B expression in human lung cancer cell lines with different pathological classification and significance. *Inner Mongolia Med Jounal*,2012, 44:4-6.

21. **Zhang**, J., X. Su, H. Lin, *et al*., Expression of EZH2 in Non-small Cell Lung Cancer and its clinical significance. *Journal of Inner Mongolia Medical University* 2013, 35:12-16.

22. Z. Chen, **Zhang**, J., X. Yang, H. Liu, and C. Van Waes. The Progression of Tumor Suppressor TP53 and the New Family Member TP63 and TP73. *Journal of Inner Mongolia Medical University* 2013, 35:57-62.

23. X.L. Su, C. Dong, **Zhang, J.**, L. Su, X. Wang, H. Cui, and Z. Chen. Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer. *Cell Bioscience* 2014, 10:7.

24. H. Lu, C. Yan, X. X. Quan, X. Yang, **Zhang, J.,** Y. Bian, Z. Chen, and C. Van Waes. CK2 Phosphorylates and Inhibits TAp73 Tumor Suppressor Function to Promote Expression of Cancer Stem Cell Genes and Phenotype in Head and Neck Cancer. *Neoplasia* 2014, 16:789-800.

25. **Zhang**, J., B. Yan, S.-S. Späth, H. Qun, S. Cornelius, D. Guan, J. Shao, K. Hagiwara, C. Van Waes, Z. Chen, X. Su, and Y. Bi. Integrated Transcriptional Profiling and Genomic Analyses Reveals RPN2 and HMGB1 as Promising Biomarkers in Colorectal Cancer. *Cell Bioscience,2015* 17, 5:53.

26. S. Mohan, R. V. Broek, S. Shah, D. F. Eytan, M. L. Pierce, S. G. Carlson, J. F. Coupar, **Zhang**, J., H. Cheng, Z. Chen, and C Van Waes. MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates anti-tumor effects in human head and neck squamous cell carcinoma. *Clinic Cancer Research* 21, 17:3946-56.

27. W. Zhu, X. Y. Zhang, S. L. Marjani, **Zhang, J.,** W. Zhang, S. Wu, and X. Pan. Next-generation molecular diagnosis: single-cell sequencing from bench to bedside. *Cell Mol Life Sci* 2017, 74:869-880

Manuscript Under Review:

1. Zhang, J., Tony, C., Hui, C, S.-S. Späth, X. Yang, R. Nussinov, Z. Chen, and Carter,V.W. Alternative NF- κ B pathway activation enhanced by deficient TRAF3 in human papillomavirus (HPV)-associated head and neck cancer.

Manuscript in Preparation:

1. **Zhang**, J., S.-S. Späth., M.Yang., S. Morton Weissman., X.H. Pan. Tumor heterogeneity and single cell analysis. The manuscript No.: 00110 in Encyclopedia of Cancer. Third Edition Section: Mechanisms. Editor: Gerd Pfeifer, to be published by Elsevier, 2018.

2.T.-F. Cheng, J. Coupar, H. Cheng, X. Yang, R. Das, **Zhang**, J., H. Si, S. Lee, C. Van Waes, and Z. Chen. Lymphotoxins activated NF- κ B signaling mediates inflammation and metastasis in head and neck squamous cell carcinomas.

3. Z. Chen, L. Bagain, M. Lian, **Zhang**, J., X. Yang, H. Cheng, E. Guven-Maiorov, L. Nicholas-Figueroa, R. Nussinov, and C. Van Waes, Aberrant expression of IL-1 family members mediate NF-kB activation and inflammation signaling in head and neck cancer.

Book Chapters:

1.Jialing, Z. The history and implication of animal model in cancer research in "The researching Method of Medical Science", Military Medical Science Press. Xiulan Su (Chief Editor). ISBN:9787802451025, First Edition, 2008,pp282-290.

2. Jialing,Z. Ethics in medical research in "The researching Method of Medical Science"， Science Publishing Company, Xiulan Su (Chief Editor). ISBN:9787030301086, Second Edition, 2011,pp10~18.

3. Jialing,Z. Progress of cancer genomics in "The researching Method of Medical Science" People's Medical Publishing House. Xiulan Su (Chief Editor). ISBN： 9787117178099, Third Edition, 2013,pp378~398.

4. Zhong, C., **Jialing, Z**., Xingpin,Y., Carter, V.W. Tumor suppressor gene TP53 and new family members TP63 and TP73 in "Year books of Chinese Clinical Oncology", Peking Union Medical College Press，Zhao Ping (Chief Editor). ISBN:978-7-81136-905-2, 2012

5.Jialing Z, Global implementation of commutated tomography colonography and Clinical Trials in the United States and Europe in "Atlas of Virtual Colonoscopy", Abraham H. Dachman and Andrea Laghi (Editors), adopted by Xueshen Shi, Chief Editor, People's Military Medical Press. 2016,pp 9~60 and 73~90.

Accepted Abstracts for Scientific Meetings:

1. Nobuyuki Koyama, **Jialing Zhang**, Hu qun, Yoshiya Goto, Yuichi Ishikawa, Yoshihiko Shimizu, Kozo Sakaguchi, Kunihiko Kobayashi, Koichi Hagiwara. Hypermethylation of semaphorin 3B promoter

in malignant pleural mesothelioma. American Association for Cancer Research, Apr 21, 2010, Philadelphia.

2. Xiulan Su, Chao Dong, Liya Su, **Jialing Zhang**, Xuemei Wang, Xia Bai, Hongwei Cui, and Zhong Chen.Anticancer bioactive peptide potentiates cisplatin chemotherapy efficacy to improve the quality of life in xenografted nude mice bearing human gastric cancer. AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, USA.

3. Tsu-Fan Cheng, Xinping Yang, Jamie Coupar, Han Si, Steven Lee, **Jialing Zhang**, Carter van Waes, and Zhong Chen.Lymphotoxins activate NF-κB-mediated inflammatory and survival pathways in head and neck squamous cell carcinomas. AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, USA.

4. Rita Das, Tsu-Fan Cheng, Jamie Coupar, Anthony Saleh, Xinping Yang, Sophie Carlson, Shaleeka Cornelius, **Jialing Zhang**, Carter Van Waes and Zhong Chen. LTβ receptor and NIK signaling activates the alternative NF-kB pathway in head and neck squamous cell carcinoma. AACR Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, USA.

Invited Editorials and Commentaries:

Tony,Chen, **Jialing Zhang,** Zhong Chen, Carter Van Waes, Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus. Cancer, 13 March 2017.DOI: 10.1002/cncr.30570